Orally administered dextran sulfate is absorbed in HIV-positive individuals

Journal of Laboratory and Clinical Medicine

Volumn 133, Issue 2, 1999, Pages 161-170

  Hiebert, Linda M ^a,b   Wice, Sandra M ^a   Jaques, Louis B ^a   Williams, Kurt E ^a   Conly, John M ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033082156     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90009-4     Document Type: Article

References (35)

1. 1. Vaheri A. Heparin and related polyionic substances as virus inhibitors. Acta Pathol Microbiol Scand 1964;171(suppl):1-97.
2. 2. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988;240:646-9.
3. 3. Ueno R, Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet 1987;1:1379.
4. 4. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res 1987;7:361-7.
5. 5. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132-6.
6. 6. Chang RS, Tabba HD, He Y, Smith KM. Dextran sulfate as an inhibitor against the human immunodeficiency virus. Proc Soc Exp Biol Med 1988;189:304-9.
7. 7. Baba M, Schols D, Pauwels R, Nakashima H, De Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J Acquir Immune Defic Syndr 1990;3:493-9.
8. 8. Bagasra O, Lischner HW. Activity of dextran sulphate and other polyanionic polysaccharides against human immunodeficiency virus. J Infect Dis 1988;158:1084-7.
9. 9. Lederman S, Gulick R, Leonard C. Dextran sulphate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 1989;143:1149-54.
10. 10. Bugelski PJ, Ellens H, Hart TK, Kirsh RL. Soluble CD4 and dextran sulfate mediate release of gp 120 from HIV-1: implications for clinical trials. J Acquir Immune Defic Syndr 1991;4:923-4.
11. 11. Busso ME, Resnick L. Anti-human immunodeficiency virus effects of dextran sulphate are strain dependent and synergistic or antagonistic when dextran sulfate is given in combination with dideoxynucleosides. Antimicrob Agents Chemother 1990;34:1991-5.
12. 12. Abrams DI, Kuno S, Wong R, Jeffords K, Nash M, Molaghan JB, et al. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989;110:183-8.
13. 13. Abrams D, Pettinelli C, Power M, Kubacki VB, Grieco MH, Henry WK. A phase I/II dose ranging trial of oral dextran sulfate in HIV p24 antigen positive individuals (ACTG): results of a safety and efficacy trial [abstract]. Fifth International Conference on AIDS, Montreal, Canada, June 19-24, 1989:404.
14. 14. Brockmeyer NH, Mertins L, Goos M. Effect of a combined dextran sulfate/zidovudine therapy compared to zidovudine monotherapy in AIDS [abstract]. Fifth International Conference on AIDS, Montreal, Canada, June 19-24, 1990:405.
15. 15. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, et al. Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med 1989;111:561-6.
16. 16. Jaques LB, Hiebert LM, Wice SM. Evidence from endothelium of gastric absorption of heparin and of dextran sulphates 8000. J Lab Clin Med 1991;117:122-30.
17. 17. Hiebert LM, Wice SM, McDuffie NM, Jaques LB. The heparin target organ - the endothelium. Studies in a rat model. Quart J Med 1993;86:341-8.
18. 18. Centers for Disease Control. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986;15:334-9.
19. 19. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:1S, 3S-15S.
20. 20. O'Dell MW, Lubeck DP, O'Driscoll P, Matsuno S. Validity of the Karnofsky Performance Status in an HIV-infected sample. J Acquir Immune Defic Syndr 1995;10:350-7.
21. 21. Jaques LB, Wice SM, Hiebert LM. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. J Lab Clin Med 1990;115:422-32.
22. 22. Jaques LB. Determination of heparin and related sulfated mucopolysaccharides. Methods Biochem Anal 1977;24:203-312.
23. 23. Nader HB, Takahashi HK, Straus AH, Dietrich CP. Selective distribution of the heparin in mammals: conspicuous presence of heparin in lymphoid tissues. Biochim Biophys Acta 1980;627:40-8.
24. 24. Takai S, Yokoyama Y, Tsubaki S. Enhancement of natural resistance of mice to Rhodococcus equi infection by dextran sulfate 500. Microbiol Immunol 1990;34:697-701.
25. 25. Alston-Smith J, Pertoft H, Laurent TC. Endocytosis of hyaluronan in rat Kupffer cells. Biochem J 1992;286:519-26.
26. 26. Hiebert LM. The uptake of heparin by liver sinusoidal cells in normal and atherosclerotic rabbits. Thromb Res 1981;21:383-90.
27. 27. Asplund J, Borell U, Holgrem H. Investigations on the storage of heparin in the animal organism as well as on the possibility of its resorption in the intestine and placenta. Anat Ann Mikrosk Anat Forsch 1939;46:16-67.
28. 28. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood L, Chaisson RE, et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2544-50.
29. 29. Chong BH. Heparin-induced thrombocytopenia. Aust NZ J Med 1992;22:145-52.
30. 30. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67:545-9.
31. 31. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
32. 32. Kishimoto S, Kobayashi H, Shimizu S, Haruma K, Tamaru T, Kajiyama G, et al. Changes of colonic vasoactive intestinal peptide and cholinergic activity in rats with chemical colitis. Dig Dis Sci 1992;37:1729-37.
33. 33. Lafeuillade A, Alessi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilichini R, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992;5:127-31.
34. 34. Bagasra O, Pestaner PJ, Bobroski L, Seshamma T, Pomerantz RJ. Localization of HIV-1 in cardiac tissue. Cell Vision J Anal Morph 1995;2:6-11.
35. 35. Bagasra O, Lavi U, Bobroski L, Khalili K, Pestaner JP, Pomerantz RJ. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ PCR and immunohistochemistry. AIDS 1996;10:573-85.